---

Revision with unchanged content. Despite widespread functional prominence and utility, modified adenoviruses have yet to prove efficacious as clinical therapeutics in the United States. Extensively characterized, modified, and employed in a multitude of clinical trials and basic research approaches over the past 20 years, adenoviral vectors have fallen short of their promise of achieving clinical efficacy in gene therapy, vaccination, and immunotherapeutic approaches. While this lack of success could be attributed to many causes, the innate immune response to adenoviral infection remains one of the most prominent obstacles to efficacious adenoviral use today. This study summarizes some recent work, using in vitro and in vivo systems, that identifies the particular innate immune responses adenoviral vectors elicit. Additionally, this work highlights some recent advances that have been made in identifying gene families and factors responsible for these responses. This book is addressed to scientists, re searchers, and medical professionals using adenoviral vectors for therapeutic means as well as researchers using these vectors as gene transfer vehicles for basic science applications.

---

Bachelor s degrees in Biology and Anthropology, Northwestern University, 2001. PhD in Genetics and Genomics in the study of adenoviral vectors at Duke University, 2006. Post-doctoral Fellow in Comprehensive Cancer Center at Duke University studying adenoviral vector approaches for immunotherapy from 2006-present.

---